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I 
 
ABSTRACT 
 
Breast cancer is the most common type of cancer to cause death in the UK (Cancer 
Research UK, 2014). Current therapeutic treatment has achieved significant success in 
reducing mortality rates but there are still a minority of patients for whom treatment is 
unsuccessful. A form of targeted therapy for breast cancer is the treatment with the 
Src/ABL inhibitor, Dasatinib. This project explores whether the transcription factor Proline 
Rich Homeodomain (PRH) mediates dasatinib sensitivity in breast tumour cells. Here we 
show that immortalised, non-tumour MCF-10A control cells are more sensitive to 
dasatinib than MCF-10A PRH knockdown cells  Similarly, tumorigenic MCF-7 control 
cells are more sensitive to dasatinib treatment than MCF-7 PRH knockdown cells 
suggesting that in both of these cell types reduced viability following dasatinib treatment 
is mediated in part through PRH. In contrast, no significant difference in dasatinib 
sensitivity was found between the highly metastatic MDA-MB-231 control cells and MDA-
MB-231 PRH knockdown cells. However, MDA-MB-231 control cells are more sensitive 
to dasatinib treatment than MCF-7 and MCF-10A control cells. We further investigated 
the molecular mechanism by which dasatinib sensitivity is mediated through PRH in the 
MCF-7 control and MCF-7 PRH knockdown cells. This thesis therefore demonstrates the 
potential role of PRH as a biomarker for dasatinib treatment of luminal breast cancer 
patients. 
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INTRODUCTION 
 
1.1 Breast Cancer 
Breast cancer is the most common cancer to cause death amongst western women. 
In 2011 49, 936 women were diagnosed in the UK with invasive breast cancer 
(Cancer Research UK, 2014). The breasts primarily function as apocrine milk-
producing glands.  Figure 1.1 illustrates the structure of the breast which consists of 
alveoli in which lactocytes can be found. Lactocytes function to secrete milk. The 
clustering of the lactocytes form a lobule and the ducts act as transporters of milk 
that secrete milk through the nipple (Help Fight Cancer, 2011).  Cancer within the 
lobules is known as lobular carcinoma and can become invasive when the wall of 
the lobule has been penetrated, indicating that the surrounding tissues of the breast 
have been invaded. Ductal carcinoma in situ (DCIS) occurs when the cancer has 
developed from the ducts of the breast and spread to surrounding areas of the 
breast tissue. (Cancer Research UK, 2012). 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Anatomy of the breast. The 
breast consists of lobules and ducts that 
predominately function to produce and secrete 
milk. Taken from (Help Fight Cancer, 2011) 
(http://www.helpfightcancer.com/learn/).  
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1.2 Subtypes of Breast Cancer 
The heterogeneous nature of breast cancer has led to the classification of various 
subtypes: basal (triple-negative), luminal (hormone-receptor-positive) and the 
Human Epidermal Receptor (HER2) (Schnitt, 2010). Basal tumours are 
progesterone (PR), oestrogen (ER) and HER2 negative and have a more 
aggressive nature compared to other tumour-types; basal tumours also have a poor 
prognosis (Schnitt, 2010). Luminal tumours are ER/PR positive where 
approximately  70% are invasive and respond well to endocrine therapy. Finally, 
HER2 tumours are ER/PR negative and are generally high grade tumours (Schnitt, 
2010). Gene expression profiling and hierarchical clustering has led to the 
identification of seven additional subtypes: luminal A, luminal B, luminal C, HER-2-
enriched (HER-2+), claudin-low, basal-related and normal breast-related (Kittaneh, 
et al, 2013). Table 1 highlights the main features for each subtype.  
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Table 1.1: Recently classified breast tumours. Taken from Kittaneh, et al, 2013 
Breast Cancer Subtype Features 
 
Luminal A 
Over express ER-regulated genes  
Under express proliferation-related genes 
Sensitive to endocrine therapy 
 
Luminal B 
Higher expression of proliferation-related 
genes 
Genetically unstable- harbour TP53 
mutations 
Higher risk of relapse 
 
Luminal C 
Distinguish from luminal A/B by their high 
expression of a set of genes with 
unknown function. For example 
transferrin receptor (CD71) 
 
HER-2+ 
High expression of HER2 proliferation 
genes Low expression of luminal clusters. 
For example luminal cytokeratins (CK) 
CK7.  
 
Claudin-Low 
Over expression of EMT-related genes.  
For example vimentin. 
No expression of luminal differentiation 
markers  
Exhibit metaplastic and medullary 
differentiation   
 
Basal-related 
ER- /PR- /HER2 -  
High frequency BRCA1 mutations 
High histological grade 
Not synonymous with triple negative (TN) 
sub-group, TN are more heterogeneous  
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1.3 Breast Cancer Therapy 
The identification of such sub-types has led to the advancement in generating 
therapeutic methods where great clinical success in patient management has 
emerged. BRCA1 and BRCA2 are proteins involved in DNA double strand repair by 
homologous recombination (Karami, and Mehdipour, 2013). Sufferers with BRCA1 
and BRCA2 mutations have a reduced survival. Risk based screening has aided 
family members with the BRCA1 and BRCA2 mutations to control their risk in 
having cancer, for example by preventative mastectomy (Hall and Easton, 2013). 
Similarly, the administration of the monoclonal antibody Herceptin (Trastuzumab) to 
patients with over expressed HER2 signalling has significantly increased patient 
survival (Slamon, 2001). At present, the first line of treatment for metastatic breast 
cancer sufferers is Herceptin and Tamoxifen for non-metastatic breast tumour 
sufferers. However, many patients have developed Herceptin resistance, further 
investigation has revealed great clinical benefit of antibody drug conjugates (ADC), 
such as Trastuzumab-DM1 (Hughes, 2010). This drug contains a special linker that 
combines the main carrier Trastuzumab to the fungal toxin DM1, which is a potent 
cytotoxic chemotherapeutic drug (Lewis-Phillips, et al, 2008). This form of targeted 
drug delivery has been shown to overcome Herceptin resistance in HER2 
expressing cells via endocytosis (Hughes, 2010). 
Targeted therapy has led to the discovery of novel therapeutic targets in breast 
cancer, for example administration of the cyclin-dependent kinase (CDK) inhibitor, 
Flavopiridol. Breast tumour cells are sensitised in vitro to TNF-related apoptosis-
inducing ligand (TRAIL)-induced apoptosis, by initiating earlier events within the 
apoptotic pathway (Munagala, et al, 2011). Dasatinib (Sprycel) is a dual Src-ABL 
kinase inhibitor approved for the treatment of imatinib-resistant/ intolerant BCR-
ABL+ leukaemia (Kantarjian, et al, 2010). Findings from ongoing-phase II clinical 
trials have shown dasatinib to have little reduction in anti-tumour activity in 
metastatic breast cancer patients, as a monotherapy (Herold, et al, 2011 and Finn, 
et al, 2011). However, administration of dasatinib in conjunction with chemotherapy 
agents like paclitaxel, leads to increased tumour stability in patients which have 
already received taxane treatment (Munagala, et al, 2011). Paclitaxel is a 
microtubule-stabilising drug that binds to the β-tubulin subunit causing cell death 
due to mitotic arrest (Zasadil and Weaver, 2012 and Zasadil, et al, 2014). However 
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it still remains unclear whether there are suitable biomarkers that can identify a 
cohort of patients that will benefit from dasatinib treatment. With the evolution of 
diagnostic and preventive techniques in breast cancer management, this project 
explores the potential therapeutic benefit of dasatinib targeted therapy, directed 
towards breast tumour cells expressing high levels of the transcription factor PRH. 
 
1.4 Dasatinib 
The potent, small molecule is a well-tolerated drug that targets members of the Src 
family kinases (SFK), c-Kit, EphA2 and PDGFR (Nautiyal et al, 2009). The inhibitor 
functions by binding to the ATP binding site and inhibits differentiation of cells in the 
blast phase of chronic myeloid leukaemia (CML) (Nautiyal et al, 2009). Dasatinib 
has a greater affinity for the ABL kinase domain compared to Imatinib, therefore has 
greater specificity. However, the inhibiting potential of Dasatinib is greater against 
Src (IC50 0.5 nmol/L) compared to ABL (1 nmol/L) (Kantarjian, et al, 2010. Figure 
1.2 shows that dasatinib has a greater inhibiting potential for Src than for EGFR, 
although both are direct targets of dasatinib. The inhibitory effects lead to a 
downstream inhibition of kinases such as AKT, MAPK and proteins that transduce 
signalling such as STAT5.  
 
 
 
 
 
 
 
 
 
Figure 1.2: Activity-based kinase assay profile of Dasatinib. Top 50 kinases 
were selected and tyrosine kinase activity was inhibited using dasatinib at an 
ATP concentration of 1 mM. Taken from Kitagawa, et al, 2012 
T
r
a
s
t
u
z
u
m
a
b
 
 
T
r
a
s
t
u
z
u
m
a
b
6 
 
1.5 Role of Transcription Factors and Chromatin Modifiers in Breast 
Cancer 
There are several transcription factors and chromatin modifiers that have been 
associated with breast tumorigenesis such as GATA-3, forkhead–box A1 (FOXA1), 
Special AT-rich Sequence-Binding protein 1 (SATB1), and TP53. Although the 
transcription PRH is not a well-known tumour suppressor, studies from our 
laboratory have shown the potential of PRH as a tumour suppressor in breast 
tumour cells (Kershaw, et al, 2013 Oncogene in press and Kershaw, et al, 
submitted). 
 
1.5.1 GATA3 
GATA3 is a transcription factor that binds to the consensus motif A/TGATAA/G and 
functions as a regulator of differentiation during embryonic development (Lowry and 
Atchley, 2000). Interestingly, GATA3 is a gene regulatory factor which functions to 
develop immature breast cells into luminal epithelial cells (Ciocca, et al, 2009).  
GATA3 is also associated with regulatory factors such as oestrogen receptor-α 
(ERα) and FOXA1 (Eeckhoute, et al, 2007). Loss of GATA3 expression has also 
been associated with reduced expression of ER. GATA3 and ER are able to auto-
regulate their own expression, leading to increased expression of GATA3 and ER in 
luminal A breast tumours (Ciocca, et al, 2008). In comparison to luminal A tumours, 
luminal B and basal-like tumours have reduced ER and GATA3 expression (Chou, 
et al, 2013). Although, a large proportion of ER+ breast tumours are known to 
respond well to hormone therapy, there are a small proportion of tumours that do 
not. Increased expression of GATA3 has been shown to be a predictor of hormonal 
response, in conjunction with better prognosis (Chou, et al, 2013). GATA3 has also 
been reported to drive invasive breast cancer cells to undergo reversal epithelial-
mesenchymal-transition (EMT), resulting in the suppression of cancer metastasis 
(Yan, et al, 2010).  Figure 1.3 highlights the frequency of GATA3 mutations in 
various breast tumour subtypes. 
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1.5.2 TP53 
The tumour suppressor gene p53 (TP53) also known as the “guardian of the 
genome”, regulates DNA damage and irregular expression of oncogenes (Horn and 
Vousden, 2007 and Walerych, et al, 2012). However, altered TP53 gene expression 
has been found in approximately 20-40% of breast carcinomas (Dale, 2003). The 
mis-regulation of TP53 activity has also been linked with the early development of 
breast carcinoma and has been reported in DCIS tumours prior to the development 
of invasive breast carcinoma (Ho, et al, 2000). Cytotoxic stress causes the 
phosphorylation of TP53 within the N-terminal domain by many kinases, resulting in 
the stabilisation of the protein (Tibbetts, et al, 1999 and She, et al, 2000).  
Consequently, TP53 forms a tetramer that binds to DNA and regulates the 
transcription of a range of TP53 target genes. These target genes have been shown 
to be involved in the regulation of the cell cycle, cell proliferation and cell survival 
(reviewed by McLure and Lee, 1998).  Figure 1.3 highlights the frequency of TP53 
mutations in various breast tumour subtypes.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Frequency of TP53 and GATA3 mutations in various subtypes of 
breast cancer. TP53 mutations are commonly observed in basal-like tumours but 
are least likely to be found in luminal A tumours. GATA3 mutations are commonly 
found luminal B subtypes but are not frequently present in basal-like and HER2+ 
tumours. Taken from Ades, et al, 2014 
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1.5.3 FOXA1 
FOXA1 is a transcription factor binds to the promoters of genes that are associated 
with cell signalling and cell cycle regulation (Habashy, et al, 2008). FOXA1 
possesses growth inhibitory properties and is a marker for various steps in 
differentiation (Habashy, et al, 2008). FOXA1 has also been shown to inhibit 
metastasis by promoting the expression of E-cadherin (Habashy, et al, 2008). 
FOXA1 binds to its consensus DNA motif which is affected by risk-associated 
single-nucleotide-polymorphisms (SNPs) that are able to alter the binding affinity of 
DNA to FOXA1. Upon oestrogen stimulation, ER is recruited to the DNA and its 
binding is mediated by FOXA1 (Meyer and Carroll, 2012). 
 
1.5.4 SATB1 
SATB1 is a protein which binds to the AT-rich regions of the DNA sequences 
(Hanker, et al, 2010). SATB1 is a transcriptional activator that is able to regulate 
cellular lineage and gene expression. The protein has also been associated with 
genes such as c-myc, where proliferation mechanisms are directly regulated by 
SATB1 (Hanker, et al, 2010). Silencing SATB1 gene expression in MDA-MB-231 
breast tumour cells, decreases cellular polarity and reduces the invasive properties 
of MDA-MB-231 cells (Hanker, et al, 2010). 
 
Expression of SATB1 has been linked with poor prognosis amongst breast tumour 
patients (Hanker, et al, 2010). Recent experimental data has shown SATB1 to be 
involved in the re-programing of chromatin modelling and transcriptional activity to 
induce growth of phenotypically aggressive breast tumours (Han, et al, 2008).  This 
investigation was able to discover a new model for gene regulation where 
expression of SATB1 modifies the gene expression profile of the tumour, proving to 
serve as a potential therapeutic target (Iorns, et al, 2008). SATB1 functions by the 
tethering of hundreds of gene loci onto its regulatory network, where chromatin 
modifying and transcription factors are assembled (Iorns, et al, 2008). The presence 
of SATB1 in the nuclei of MDA-MB-231 cells is of great prognostic value in patients, 
independent of their lymph node status (Iorns, et al, 2008). 
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1.6 PRH 
Proline-Rich-Homeodomain (PRH) is also known as the haematopoietically 
expressed homeodomain (HHex) and PRH is crucial in the haematopoietic system 
(Soufi, et al, 2008). PRH is a transcription factor that has a length of 270 amino 
acids and molecular weight of 30 kDa and PRH regulates cell differentiation, 
proliferation and migration (reviewed by Soufi, et al, 2008, Noy, et al, 2010 and 
Kershaw, et al 2013). The protein has three domains: N-terminal domain, 
homeodomain and the C-terminal domain as illustrated in figure 1.4.  PRH regulates 
cell proliferation via protein-protein interactions that influence the cell cycle (Soufi, et 
al, 2008).It is able to regulate cellular development by modulating gene expression 
through transcriptional and post-transcriptional mechanisms (Soufi, et al, 2008). 
PRH has also been found to be expressed in organs of adult cells such as the 
thyroid (D’Elia, et al, 2002) and liver (Denson, et al, 2000), where it is vital in 
regulating the cellular proliferation and differentiation of these cells (Soufi, et al, 
2008). The mis-localisation and altered subcellular distribution of PRH has been 
associated with malignancies such as leukaemia (George, et al 2003), breast 
(Puppin, et al, 2006) and thyroid cancer (D’Elia, et al, 2002).  
 
   
 
 
 
 
Figure 1.4: Structure of PRH. PRH consists of three major domains, the proline-
rich N-terminal domain (green), the DNA binding site, homeodomain (blue) and the 
acidic C-terminal domain (red). The different domains also contain various sites 
where PRH is able to interact with DNA and proteins such as TLE. The 
homeodomain is the site of PRH phosphorylation where the two serine residues are 
phosphorylated by CK2. Adapted from Soufi, et al, 2008. 
 
 
 
 
   NT HD CT 
   
0 137 50 197 270 
 Ser Ser
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1.6.1 N-Terminal Domain 
The N-terminus of the protein (AA 1-137) is proline-rich and fundamentally 
important in the oligomerisation of PRH (Soufi et al., 2008). This region also 
contributes to transcriptional repression through the binding of PRH, to the co-
repressor Groucho/TLE (transducing-like enhancer) co-repressor family. The N-
terminal domain is also involved in interactions with protein kinase CK2β subunit, 
promyelocytic leukaemic (PML) protein and the translation factor eIF-4E (Soufi, et 
al, 2008). PML is a co-repressor for transcription factors like the tumour suppressor 
protein Mad and SATB1 (Soufi, et al, 2008). 
 
1.6.2 Homeodomain  
The PRH homeodomain is 60 amino acids in length and is able to bind DNA at the 
consensus binding site 5’-C/TA/TATTAAA/G-3’. Generally homeodomains are 
present in proteins that form monomers, hetero-dimers and hetero-trimers on the 
binding of DNA. However, PRH is a very unique protein as it is able to form homo-
oligomeric octamers and hexadecamers in vitro and in cells (Soufi, et al, 2008). This 
has led to the observation that PRH binds to genes via multiple tandem DNA PRH 
binding sites through a mechanism that does not involve a well-defined recognition 
site (reviewed by Kershaw, et al, 2012). The binding of DNA does occur through the 
recognition helix of the homeodomain, positioned in the major groove. The arm of 
the N-terminus of the homeodomain aids DNA binding by the DNA, by targeting 
specific base pairs in the adjacent minor groove. The resultant loop interacts with 
the phosphate backbone of DNA (Soufi, et al, 2008). The homeodomain contains 
two serine residues, amino acids 163 and 177 in human PRH. Phosphorylation of 
the serine residues by the protein kinase CK2 inactivates PRH, in that it abolishes 
DNA bindings and decreases nuclear retention (Soufi, et al, 2008).  
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1.6.2 C-Terminal Domain 
This domain largely involves transcriptional activation and has been shown to be 
linked to the activation of the bile transporter gene NTCP (sodium- dependent bile 
acid co-transporter) (Sato, et al, 2004). Through the aid of the homeodomain PRH 
is able to bind to this promoter and activate transcription. The activation region 
involves the carboxyl-terminal area, with amino acids 197 to 271 human residues of 
PRH (Sato, et al, 2004 and Denson, et al, 2000, reviewed by Soufi, et al, 2008). On 
deletion of the amino acid residue 197 to 216 in PRH, results in a huge decline in 
promoter activity by approximately 50%. This strongly indicates that the homeo 
domain is imperative for maximal transcriptional activation (Soufi, et al, 2008). 
 
1.6.3 Oligomerisation 
Cross-linking studies have revealed PRH forms oligomers within cells (Soufi, et al, 
2006, Swingler, et al, 2004 and Topcu, et al, 1999).  Pull-down assays have 
identified two regions within the N-terminus which are involved with self-association; 
additionally the homeodomain is also involved in self-association (Soufi, et al, 2006, 
reviewed by Soufi, et al, 2008). Analytical ultra-centrifugation (AUC) sedimentation 
velocity investigations have found that the oligomeric form of PRH binds to DNA 
(Soufi, et al, 2006).  The oligomeric form of PRH binds with a relatively high affinity 
to DNA binding sites (Bess, et al, 2003 and reviewed by Soufi, et al, 2008).  PRH 
can also cause transcriptional repression whereby it interacts with the Groucho/TLE 
co-repressor and recruits TLE proteins to a subgroup of promoter targets 
(Brickman, et al, 2000, Zamparini, et al, 2006 and Cong, et al, 2006). This is 
depicted in figure 1.5. Oligomeric TLE/proteins can recruit histone deacetylases 
leading to the binding of TLE proteins to hypo-acetylated chromatin, resulting in a 
repressive chromatin domain (reviewed by Soufi, et al, 2008). 
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Figure 1.5: Model depicting the oligomerisation states of the PRH protein. The 
open state of chromatin is able to bind to PRH octamers (green) to various sites 
within the target promoter. The self-association of PRH along the chromatin 
eliminates the transcription machinery, resulting in transcriptional repression- 
repressed state. The condensed state of the chromatin leads to the recruitment of 
co-repressors such as Groucho/TLE. Taken from Soufi and Jayaraman 2008. 
 
1.6.5 PRH Phospho-protein 
Phosphorylation of PRH reduces its DNA binding ability and blocks transcriptional 
repression by PRH, at many PRH-dependent target genes (Soufi, et al, 2009). PRH 
binds specifically to the β subunit of CK2 leading to the phosphorylation of PRH by 
CK2 subunits at serine residues 163 and 177 (Soufi, et al, 2009). A mutant PRH 
protein containing glutamic acid residues instead of serine residues at the 
phosphorylation sites within the PRH homeodomain, has a reduced ability to bind 
tightly within the nucleus (Noy, et al, 2012). This signifies that a decrease in nuclear 
retention of PRH occurs upon phosphorylation. The phosphorylation of PRH leads 
to the formation of its truncated product, PRHΔC, by the proteasome. The PRHΔC 
protein functions as a trans-dominant negative protein relative to endogenous PRH 
by sequestering the PRH co-repressor protein (TLE) (Noy, et al, 2012). Thus, PRH 
phosphorylation is a potent mechanism of inactivation of PRH and a potential 
mechanism for the regulation of cell proliferation. 
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1.7 Role of PRH in Haematopoiesis 
PRH is present in species such as Xenopus and zebra fish (Ho, et al, 1999 and 
Jones, et al, 1999). PRH mRNA was identified in extra-embryonic tissues that are 
involved in the anterior-posterior axis formation (Thomas, et al, 1998 and reviewed 
by Soufi, et al, 2008). The protein has been found within embryonic cells and 
mesodermal tissues that give rise to haematopoietic and vascular progenitors (Keng 
et al, 1998 and Bogue et al, 2000).  Loss of Prh within the haemangioblast causes a 
decrease in the differentiation of haematopoietic cells (Guo, et al, 2003).  Moreover, 
haematopoietic stem cells exhibit high levels of PRH but PRH expression is 
reduced during differentiation (Manfioletti, et al, 1995).  
 
1.8 PRH and Cancer 
Aberrant subcellular localisation of the PRH protein has been associated with 
cancers such as leukaemia (Topisirovic, et al, 2003) breast (Puppin, et al, 2006) 
and thyroid (D’Elia, et al, 2002). The expression of the fusion protein PRH-NUP98 
has been shown to induce acute myeloid leukaemia (AML) and is thought that PRH-
NUP98 functions as a trans-dominant negative protein in wild-type PRH and 
activates genes that PRH normally represses. (Jankovic, et al, 2008). Nuclear 
localisation of PRH has also been shown to be reduced in breast and thyroid 
cancers, as PRH expression has been found in nuclear and cytoplasmic normal 
breast thyroid carcinomas (Puppin, et al, 2006 and D’Elia, et al, 2002). Furthermore 
PRH expression is decreased in less differentiated hepatocarcinomas that are 
known to be more aggressive (Su, et al, 2012). 
 
1.8.1 PRH and Leukaemia 
Past research has revealed that within CML, eIF4E is involved in the modulation of 
cellular growth (Topisirovic, et al, 2003).  eIF4E associates with PML and transports 
nucleo-cytoplasmic specific transcripts which contribute to the transformation of 
cells in CML (Topisirovic, et al, 2003). PRH is a tissue-specific inhibitor of eIF4E 
dependent cyclin- D1 mRNA transport and growth of PML, by causing cell cycle 
arrest and reducing cell proliferation (Topisirovic, et al, 2003). Interestingly, eIF4E 
binds to PRH but the functional significance of this inactivation is not yet known 
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(Bordin, et al, 1999).  PRH has been observed to have a punctuate pattern within 
the nucleus and cytoplasm of the leukemic K562 cell line, where PRH and PML 
both possess an inhibitory growth control function (Bordin, et al, 1999). 
 
1.8.2 PRH and Breast Cancer 
The mis-localisation and alteration in the sub-cellular distribution of PRH is reported 
to be associated with the development of breast tumorigencity (Puppin, et al, 2006). 
PRH is reported to be predominantly cytoplasmic in breast tumour cells and is also 
sequestered in the nucleolus of MCF-7 cells (Puppin, et al, 2006). However, 
generation of an MCF-7 PRH knockdown cell line has shown that cells have 
increased proliferation and survival. This has led to the conclusion that some 
endogenous PRH remains active within the nucleoplasm of MCF-7 cells (Noy et al., 
2010), despite the nucleolar localisation (Puppin, et al, 2006).  Overexpression of 
PRH inhibits cell migration and invasion of breast tumour cells (Kershaw et al., 
2013). Moreover, PRH regulates the transcription of the genes involved in the 
Vascular Endothelial Growth Factor (VEGF) pathway, within the MCF-7 cell line 
(Noy, et al, 2010). 
 
1.9 PRH and Growth Control in K562 cells 
Dasatinib does not directly bind to CK2 but dasatinib treatment blocks the formation 
of the phosphorylated and inactive form of PRH. This inhibition of CK2 is attributed 
to the decreased Src signalling as CK2 and Src protein interact directly (Noy, et al, 
2012). Knockdown of PRH in K562 cells show increased VEGF signalling as PRH 
represses the transcription of multiple genes that encode the proteins of the VEGF 
signalling pathway (Noy, et al, 2012).  Dasatinib treated K562 cells have decreased 
levels of phosphorylated PRH (pPRH). By inference it is thought that there is more 
active PRH in cells to re-establish the repression of genes encoding the VEGF 
signalling pathway, resulting in decreased leukemic cell survival (Noy, et al, 2012).  
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1.10 Tyrosine Kinase- Src 
Src belongs to a major family of non-receptor protein tyrosine kinases: Lyn, Fyn, 
Yes, Lck, Fgr, Hck, Blk and Yrk. Figure 1.6 shows the structure of Src. The 60-kDa 
tyrosine kinase can be activated by the focal adhesion kinase (FAK) or the Crk-
associated substrate (CAS), involved in integrin signalling (Roskski, 2004). 
Activation can also occur via cell surface receptors such as the epidermal growth 
factor (EGFR). Such molecular interactions cause disruptions in the intramolecular 
interactions within Src; forming an open conformation of Src (Ishizawar and 
Parsons, 2004). This facilitates the interaction with various substrates such as 
downstream signalling molecules. Full activation of Src occurs through the auto-
phosphorylation of the tyrosine residue Y419 which is preserved in the catalytic 
domain. 
 
 
 
 
 
 
 
 
 
 
 
 
    
SH4 
SH3 SH2 Catalytic  
Y419 unique 
C-Terminal  
Y530 
M 
Figure 1.6: Structure of Src. Src consists of the myristylation site (M), Src homology (SH) 
domains, catalytic domain, unique domain and the c-terminal negative regulatory tyrosine 
residue. The unique domain is known to vary the most between the Src family kinases. 
Taken from Finn, et al, 2008 and Sicheri and Kuriyan, 1997. 
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1.10.1   Role of Src in Breast Tumour Cells 
Elevated activity of Src has been observed in breast cancer where it plays a critical 
role in the crosstalk between growth-promoting pathways, like the EGFR pathway 
(Ishizawar and Parsons, 2004). Src mediates mitogenic effects of oestrogen directly 
and indirectly, this is important for evaluating the benefits of steroid hormone 
receptors. This is strongly supported by experimental evidence where Src- deficient 
cell lines do not activate the mitogen-activated protein kinase by oestrogen. Src is 
also a critical intermediate by promoting downstream effects of receptor tyrosine 
kinase activity (RTKs), such as EGFR and is commonly related to the therapeutic 
target HER2 (Ishizawar and Parsons, 2004). 
Phosphorylated tyrosine residues are a result of auto- transphosphorylation of the 
activated tyrosine kinase domain, resulting in the activation of several cell-signalling 
pathways (Ishizawar and Parsons, 2004). Figure 1.6 illustrates the complexity of the 
various pathways that Src plays a key role as a regulator.  Breast cancer cell lines 
with increased expression of HER2 and Src have high levels of phosphorylated Src 
in conjunction with activation of the mitogen-activated protein kinase (MAPK). This 
leads to increased levels of tumorigencity compared to cell lines that are EGFR and 
Src deficient (Ishizawar and Parsons, 2004). 
Src functions by mediating the activation of the signal transducer and activator of 
transcription (STAT) RTKs (Okutani, et al, 2001). Inhibition of the Src pathway leads 
to decreased levels of STAT3 within breast tumour cell lines that express increased 
levels of EGFR (Ishizawar and Parsons, 2004). Src is also involved in the 
downstream activation of HER2 and the potential role of HER2-HER3 interactions 
(Belsches-Jablonski, et al, 2001). Over-expression of Src enhances the dimerisation 
between HER2-HER3. Requirement of Src for tumour cell motility and anchorage 
independent growth is promoted by the dimerised complex HER2-HER3 (Belsches-
Jablonski, et al, 2001). Increased expression of Src has also been observed in 
invasive breast tumour cell lines compared to non-invasive, where treatment with a 
SFK inhibitor decreases in breast tumour invasion and motility (Belsches, et al, 
2001). 
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Figure 1.7: Src mediated signalling pathways that contribute to the progression 
of tumorigenesis.  Members of the SFK are intermediates in many different 
signalling pathways. The association of Src with the over-expression of mutated 
tyrosine kinase receptors, results in constitutively active Src to activate pro-survival 
pathways (green) and the angiogenic pathways (blue). Increased proliferation occurs 
when Src is activated by both receptor tyrosine kinases and focal adhesion kinase 
(FAK) (brown). Crosstalk between the various pathways also occurs with many of the 
intermediates between these pathways involved in the activation of Src.  Adapted 
from Summy and Gallick, 2006. 
 CK2 
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1.11 Cell lines 
The Jayaraman laboratory has shown that overexpression of PRH in MCF-7, MCF-
10A and MDA-MB-231 cells inhibit cell proliferation and cell migration. Thus, PRH is 
a potential regulator of breast tumorigenicity. MCF-7, MCF-10A and MDA-MB-231 
cell lines were used for all experimental work in this project.  
MCF-7 cells are derived from a pleural effusion from a 69 year old metastatic breast 
cancer patient (Levenson, et al, 1997). The cells are negative for HER2 
amplification but express wildtype p53 (Subik, et al, 2010). MCF-7 cells are of 
luminal origin, specifically categorised as luminal A and form tightly cohesive 
structures (Holliday et al 2011). MCF-7 cells are characterised with an “epithelial-
like” phenotype due to high levels of E-cadherin expression and low levels of 
Vimentin expression. Matrigel experiments have shown MCF-7 cells to be weakly 
invasive and to form spherical colonies (Lacroix and Leclercq, 2004). 
MDA-MB-231 cells are derived from pleural effusion from a 51 year old female 
patient and grow as a monolayer. MDA-MB-231 cells are tumorigenic in nude mice 
and grow to form a poorly differentiated adenocarcinoma. MDA-MB-231 cells also 
lack oestrogen receptors and exhibit oestrogen-independent growth, giving this cell 
line a more aggressive phenotype than MCF-7 (Thompson, et al, 1992).  They are 
known as triple negative as they lack ER, PR and HER2 expression but possess a 
basal-like phenotype (Lacroix and Leclercq, 2004). The cells also express a 
mutated form of p53 (R280K) enhancing tumour survival (Hui, et al, 2006).  Due to 
the MDA-MB-231 cells being highly invasive they form stellate colonies in Matrigel 
and are characterised as being “mesenchymal-like” (Lacroix and Leclercq, 2004). 
MCF-10A cells are non-tumorigenic and do not form tumours in nude mice but are 
unable to undergo anchorage-independent growth in Matrigel (Soule, et al, 1990). 
They are an immortalised cell line derived from normal diploid mammary epithelium 
(Soule, et al, 1990). MCF-10A cells lack SV40 T antigen and HER2 amplification, 
they are positive for wild-type p53 expression (Soule, et al, 1990). The MCF-10A 
cell line is a good model for studying normal untransformed breast cells, when 
grown in 3D culture they form acinar structures that are phenotypically similar to 
mammary glands (Debnath, et al, 2003) 
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1.12 Generation of MCF-7, MCF-10A and MDA-MB-231 Knockdown Cell Lines 
The inducible MCF-7 PRH knockdown cell line and the MDA-MB-231 PRH 
knockdown cell lines used for all experimental work were generated by Dr Daniel 
Roberts in the Jayaraman laboratory (Roberts, 2014). PRH expression was 
knocked down using specific shRNA sequences against the PRH open reading 
frame. The PRH shRNA sequences are under the control of the U6 promoter, which 
contain an engineered lac operator site. A lenti-viral vector integrates the DNA 
encoding shRNA sequences randmly into the genome and the vector also encodes 
the lac repressor cDNA and a resistance maker gene (puromycin). Upon integration 
the lac repressor is expressed along with the resistance marker gene. The lac 
repressor binds the lac operator repressing expression of the U6 promoter. Upon 
induction with isopropyl-β-D-1-thiogalactopyranoside (IPTG), the allosteric lac 
repressor alters its conformation to release itself from the lac operator in the U6 
promoter, allowing expression of the shRNA.  The resulting pre-shRNA is exported 
from the nucleus by exportin 5. The enzyme dicer processes the product and the 
resulting processed shRNA are encompassed within the RNA- induced silencing 
complex (RISC).  The sense strand is degraded whilst the anti-sense strand leads 
the RISC complex to the mRNA, containing a complementary sequence. RISC 
functions to cleave either the mRNA or repress translation of the mRNA, resulting in 
the shRNA to silence its target gene, in this case the PRH genetic sequence. Figure 
1.8 depicts this genetic process and figure 1.9 confirms that PRH knockdown was 
successfully achieved in the MCF-7, MCF-10A and MDA-MB-231 cells.  
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Figure 1.9: Inducible Knockdown of PRH in MCF-10A, MCF-7 and MDA-MB-231 
cells. Each cell line was infected with a lenti-virus containing shRNA for either PRH 
knockdown or against no known mammalian gene, this acted as the control. The 
infected cells were selected with 0.5 µg/ml puromycin for 7 days; this was followed by 
induction of shRNA expression using 1mM IPTG. Cells were then pelleted and after 7 
days of induction, protein was extracted for separation by SDS-PAGE and probed with 
the PRH antibody-M6 to confirm successfully knockdown of PRH. Taken from Roberts, 
2014. 
 
Figure 1.8: Generation of the inducible MCF-7 and MDA-MB-231 PRH 
knockdown cell line.  A lenti-virus containing specific shRNA sequences 
against the PRH open reading frame, was randomly integrated into the cell. 
Polymerases II and III transcribed the shRNA. The pre-shRNA was exported 
via Exportin 5 from the nucleus and processed by DICER. The processed 
shRNA was encompassed within the RISC complex and shRNA silenced the 
genetic expression of PRH, resulting in successful PRH knockdown.  
MCF-7 MDA-MB-231 
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1.13 Microarray Analysis 
A gene expression microarray was carried out by Dr Rachael Kershaw in the 
Jayaraman laboratory, to compare mRNA expression in the MCF-7 control and 
PRH knockdown cells (Kershaw, et al, submitted). The gene expression profile was 
assessed by quantitative real-time PCR (qRT-PCR) of genes. Figure 1.10 shows 
expression levels of cyclin-D2 and Vimentin to validate the microarray.  
 
 
 
 
 
 
 
Figure 1.10: (A) Microarray data for the altered gene expression levels detected 
in the MCF-7 PRH control and knockdown cells. The mRNA expression data for 
each gene is presented as a matrix where rows represent individual genes and 
columns represent the individual mRNA samples for three independent control (C1-C3) 
and PRH knockdown (KD1-KD3) cell lines. The genes selected are genes with known 
function in cellular proliferation/survival, differentiation or cancer-stem cell renewal. The 
colour scale at the bottom is the relative level of gene expression. (B) Relative 
expression of genes by qRT-PCR: Cyclin D2 and Vimentin. The expression levels 
of both genes were normalised to GAPDH mRNA. (Kershaw, et al, submitted) 
(A) 
(B) 
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1.13.1  Overview of the MCF-7 PRH Knockdown cell line 
The tumorigenic MCF-7 PRH knockdown cell line has increased proliferation, 
migration and invasion (Noy, et al, 2010 and Kershaw, et al, 2013). Moreover, 
unpublished studies in the Jayaraman laboratory have observed the MCF-7 
knockdown cells to express epithelial-mesenchymal-transition (EMT) markers such 
as Vimentin, Slug and Snail. MCF-7 PRH knockdown cells have also been 
observed to express cancer stem cell markers like CD44+ as well as having the 
potential to form mammospheres (Roberts, 2014). 
 
1.14 Aims 
Since the MCF-7 knockdown cells have cancer stem cell properties it was 
hypothesised that the PRH knockdown cells may be resistant to conventional 
chemotherapy treatment and to dasatinib targeted therapy. Therefore the main aim 
of this project was, to determine whether the highly tumorigenic MCF-7 PRH 
knockdown cell line is resistant to dasatinib treatment and to further investigate the 
molecular basis for this resistance. A second aim was to investigate whether the 
immortalised breast cell line MCF-10A and the highly aggressive MDA-MB-231 cell 
lines have decreased PRH expression and are resistant to dasatinib treatment.  
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MATERIALS & METHODS 
 
2.1 Summary of used chemicals and reagents in this project 
 
Table 2.1: Chemicals and reagents 
Chemical Information 
Antibodies Anti-Lamin A/C (H-110) (Santa 
Cruz sc-20681): Rabbit 
Polyclonal 
 
Anti-phospho PRH (YKN5): 
Rabbit Polyclonal (In house) 
 
Anti-alpha pan SRC: Rabbit 
Polyclonal 
 
Anti-phospho Src (Y416): 
Rabbit Polyclonal (Cell 
Signalling Technology #2101S) 
 
Anti-phospho XRCC1 (S485/ 
T488): Rabbit Polyclonal (Bethyl 
Laboratories Cat: A300-231A) 
 
Anti-PRH (M6): Mouse 
polyclonal 
 
Anti-mouse IgG HRP 
conjugated-Goat (Santa Cruz 
Biotech sc-2005) 
 
Anti-rabbit IgG HRP conjugated-
Goat (Santa Cruz sc-2313) 
 
Bovine Serum Albumin (BSA) First Link (UK) Ltd. Cat. 40-00-
450 
Bradford Reagent Bio-Rad 500-001 
Caesin Kinase II Inhibitor VI, TMCB Calbiochem 218718 
Cholera Toxin Sigma C8052 
Complete (protease inhibitor 
cocktail tablets) 
Roche  04 693 124 001 
Dasatinib, free base LC Laboratories D-3307 
Dimethyl Sulfoxide (DMSO) Sigma D8418 
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DMEM/F12 Ham L-glutamine and 
15 mM HEPES 
Sigma D8437 
Epidermal Growth Factor (EGF) Peprotech AF-100-15 
Ethanol Fisher Scientific 
Ethylenediaminetetraacetic acid 
(EDTA) 
Sigma E5134 
Fetal Bovine Serum (FBS) Sigma F7524 
Glycine Sigma 241261 
Horse serum- heat inactivated Sigma H1138 
Hydrocortisone Sigma H0888 
Insulin Solution Human Sigma I9278 
Isopropyl-β-D-1-
thiogalactopyranoside (IPTG) 
Bioline 37036 
Magnesium Chloride Sigma M8266 
Methanol Fisher Scientific 
Pageruler Plus Protein Ladder Fermentas- PageRulerTM Plus 
Prestained Protein Ladder 
(SM1811) 
PBS Tablets Sigma P4417 
Penicillin/ Streptomycin Sigma P4333 
Polyoxyethylene Sorbitan 
Monolaurate (Tween 20) 
Sigma P1379 
Ponceau S Solution Sigma P7170 
Potassium Chloride Sigma P9541 
Potassium Phosphate (KH2PO4) Sigma P9791 
Puromycin Gibco by Life Technologies 
(A1138-03) 
RPMI 1640 medium Sigma R8758 
Sodium Azide Sigma S8032 
Sodium Chloride Sigma S9888 
Sodium deoxycholate Sigma D6750 
Sodium dodecyl sulfate (SDS) Sigma L4509 
N,N,N,N- 
Tetramethylethylenediamine 
(TEMED) 
Sigma T9281 
Thiazoly blue formazan [1-4,5-
dimethylthiazol-2-yl)-3,5-
diphenylformazan] (MTT) 
Sigma M2003 
Trizma Base Sigma T4661 
Trypsin-EDTA (10X) PAA L11-003 
Β-mercaptoethanol Sigma M6250 
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Table 2.2: Summary of used solutions 
Solution Information 
1X PBS 137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
2 mM KH2PO4 
Adjusted to pH 7.4 
 
Table 2.3: Summary of solutions for whole cell protein extraction 
Solution Information 
RIPA Buffer 50 mM Tris-Cl (pH7.5) 
150 mM NaCl 
1% v/v Np-40 
0.5% v/v Sodium Deoxycholate 
0.1% v/v SDS 
Protease inhibitor tablet 
2X Laemmli Buffer 62.5 mM Tris- HCL ph 6.8 
25 % glycerol 
2% SDS 
0.01% Bromophenol Blue 
 
 
Table 2.4: Summary of SDS polyacrylamide gel solutions 
Solution Information 
1X Resolving Buffer 375 mM Tris-Cl     (final pH 8.8) 
0.1% w/v SDS 
1X Stacking Buffer 125 mMTris-Cl      (final pH 6.8) 
0.1% w/v SDS 
SDS polyacrylamide resolving gel 1X resolving buffer (see above) 
Acrylamide  
0.1% Ammonium Persulfate 
TEMED 
SDS polyacrylamide stacking gel 1X stacking buffer (see above) 
4.5% acrylamide 
0.1% Ammonium Persulfate 
TEMED 
 
Table 2.5: Summary of solutions for SDS-Polyacrylamide Page Gel 
Electrophoresis (PAGE) 
Solution Information 
1X Running buffer 25 mM Tris-Cl 
192 mM Glycine 
0.1% w/v SDS 
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Table 2.6: Summary of solutions used for the transfer of proteins from SDS-
PAGE to Immobilon-P Membrane 
Solution Information 
1X Transfer buffer 10 mM Tris-Cl 
100 mM Glycine 
0.05% w/v SDS 
20% v/v Methanol 
 
Table 2.7: Summary of solutions used for antibody detection 
Solution Information 
PBS-Tween 1X PBS 
0.05% Tween 20 
Primary Blocking Solution 3% w/v Bovine Serum Albumin 
(BSA) 
3 mM Sodium Azide in PBS-
tween 
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2.2 Cell Culture Protocols 
2.2.1 Adherent Cell Culture 
MCF-7 and MDA-MB-231 cells were maintained in Roswell Park Memorial Institute-
1640 (RPMI-1640) medium. The medium was supplemented with 10% foetal bovine 
serum (FBS)-heat inactivated at 56°C for 30 minutes, 100 units/ ml penicillin, 100 
µg/ml streptomycin. Induction medium (RPMI+I) was prepared following the same 
protocol, with the addition of 1 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) 
and 0.5 μg/ml puromycin at final concentration. Cells were maintained in a 
humidified incubator at 37°C, within an atmosphere of 20% oxygen, 5% carbon 
dioxide and 75% nitrogen. For PRH knockdown experiments cells were used only 
when induced with IPTG for at least 7 days. Cells were checked regularly using the 
microscope (Leica DMIL/ 090-131.001) for confluence and absence of 
contaminants. Cells were split when confluent, approximately every two days. The 
cell monolayer was washed with 1X PBS, followed by trypsinisation with 1X trypsin-
EDTA for cell detachment at 37°C for 3 minutes. An equal volume of RPMI was 
added to the cells and centrifuged at 1000 rpm for 3 minutes (Harrier 18/80- 
A050169). Cells were re-suspended in RPMI and transferred to a new flask. Both 
cell lines were grown in Starstedt tissue culture flasks. MCF-10A cells were 
maintained in Dulbecco’s Modified Eagle Medium/F12 (DMEM/F12), supplemented 
with 5 % horse serum (heat inactivated), 20 ng/ml epidermal growth factor (EGF), 
0.5 µg/ml hydrocortisone, 100 ng/µl cholera toxin, 10 µg/ml insulin and 100 units/ ml 
penicillin, 100 µg/ml streptomycin (Sigma P4333). The cells were maintained and 
split as described above and grown in Falcon tissue culture flasks.  
 
2.2.2  Dasatinib  
0.5 g of dasatinib was dissolved in 20 ml DMSO to make a stock concentration 50 
mM, by filter sterilisation. 1 ml aliquots were stored at -20°C. Final concentrations of 
0.05 µm, 0.1 µm, 0.5 µm, 1 µm and 5 µm were made in the induction medium from 
the 50 mM stock. 
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2.2.3 Cell Viability Assays  
 
Cells were counted by trypan blue exclusion, 10 µl trypan blue was mixed with 10 µl 
cells in medium. The number of viable cells was calculated using the 
haemocytometer and the formula:  
 
Number of cells/ml = Average count per square x dilution factor x 104 
 
Induced cells were seeded at ~5 x 104 cells/well in 200 µl induction medium within a 
96-well plate and incubated overnight at 37°C. MCF-7 cells were incubated with 
0.05 µm, 0.1 µm, 0.5 µm and 1 µm dasatinib for 72 hours, with equivalent volumes 
of DMSO. 200 µl MTT (0.5 mg/ml) was added to each well and the plate was 
incubated for 2 hours at 37°C. 100 µl DMSO was added and the plate was placed 
on a rocking platform to allow complete solubilisation of the MTT crystals. The 
resulting formazan product produced a colorimetric change, indicative of the total 
cellular metabolism. The optical density (OD) was measured at 545 nm using the 
Emax ELISA plate reader. The results were expressed as a relative % of total 
cellular activity compared with the corresponding untreated controls (expressed as 
100%).  
 
2.3 Western Blot Protocols 
2.3.1 Extraction of Whole Cell Protein 
Whole cell extracts were created from 1 x106 dasatinib treated/ DMSO equivalent 
MCF-7 cells in 6 well plates. Adherent cells were washed with 1 ml 1X PBS, 
trypsinised with 500 µl 1X trypsin and re-suspended in 500 µl medium. Contents 
from each well of the 6 well-plate were transferred into sterile 1.5 ml eppendorf 
tubes and cells were pelleted by centrifugation for 3 minutes at 3000 rpm 
(Eppendorf 5810R). The supernatant was discarded and a second wash with 1X 
PBS was performed, followed by centrifugation. The pellet was re-suspended in 100 
µl RIPA buffer and incubated on ice for 15 minutes for cell lysis. Cell debris was 
removed by centrifugation at 13000 rpm (Thermo Scientific Heraeus Fresco 21) at 
4°C for 30 minutes. The supernatant was collected into a sterile eppendorf tube and 
stored at -80 °C.  
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2.3.2 Determination of Protein Concentration 
Protein concentration was determined using the Bradford method (Bradford.M, 
1976), BSA was used as a standard and diluted to 0 µg, 2 µg, 4 µg, 6 µg and 10 µg 
within Bradford reagent (1:5, Biorad). The samples were read 
spectrophotometrically after blanking the machine with RIPA buffer. Figure 1 was 
plotted and the gradient used to determine protein concentration, using the Beer-
Lambert law. This consists of using the equation: A=Ɛcl where absorbance is 
proportional to the concentration of the molecule being absorbed (c), length of path-
light (l) and the molar extinction coefficient (Ɛ). All concentrations of protein samples 
for SDS-PAGE were calculated using figure 2.1.  
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Figure 2.1: Bradford Assay. Used to determine protein concentration 
by using the Beer-Lambert law A=Ɛcl.  
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2.3.3 Preparation of SDS-Polyacrylamide Gel 
The front and back glass plates (Bio-rad) were clamped into the casting frame 
which was clamped into the casting stand. The resolving gel was prepared with 
gentle swirling see table 2.4, and the solution was pipetted between the glass 
plates. 1 ml isopropanol was added to remove the air-water interface and the gel 
was left to polymerise for at least 15 minutes. The isopropanol was discarded and 
the stacking gel was prepared, see table 2.4 This was pipetted on top of the 
resolving gel to the brim of the plates and a 1 mm comb was inserted into the 
stacking gel and left to polymerise for at least 15 minutes.  
 
2.3.4 Separation of Proteins by Molecular Weight 
All protein samples were heated at 95°C for 5 minutes with 1X Laemmli buffer prior 
to being loaded onto the gel. The SDS gel was inserted within the separation tank 
(Bio-Rad Mini-PROTEAN Tetra Electrophoresis System). The protein samples were 
loaded onto the gel, with PageRuler Plus prestained Protein Ladder (Fermentas 
SM1811). The gel was electrophoresed at 130V (constant voltage) for 90 minutes.  
 
2.3.5 Transfer of Proteins from SDS-polyacrylamide 
Transfer apparatus (Bio-Rad Mini Trans-Blot Cell System) was used where the 
Immobilon-P membrane (Millipore IPVH00010) was left in methanol for 30 seconds, 
for hydration and washed in distilled water for 2 minutes. The membrane was 
equilibrated in 1X transfer buffer for 3 minutes. 3MM Whatman filter paper 
(Whatman 3030917) was soaked in 1X transfer buffer. Once protein separation had 
occurred, the gel was removed from between the plates and the stacking gel 
discarded. The pad and 3MM Whatman filter paper were placed on the cathode 
side of the transfer cassette, followed by the gel on top, Immobilon-P membrane on 
top of the gel, 3MM Whatmann filter paper on top and finally the pad on top. The 
transfer cassette was firmly closed and assembled into the apparatus and the tank 
was filled 1X transfer buffer. The transfer occurred at 70V (constant voltage) for 1 
hour.  
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2.3.6 Detection using antibodies  
The membrane was soaked in methanol for one minute and washed thoroughly in 
1X PBS-Tween. The membrane was soaked in Ponceau S solution for five minutes 
for identification of successful protein transfer and removed with several PBS-
Tween washes. The membrane was left overnight in PBS-Tween containing 10% 
(w/v) milk at 4°C on a rotating platform. The membrane was washed 3 times for 10 
minutes in PBS-Tween for removal of milk and then probed for a specific primary 
antibody, by being incubated in primary blocking solution for one hour.  Additional 
three 10 minute washes in PBS-Tween were performed and a one hour incubation 
in secondary antibody, diluted in 1X PBS-Tween solution containing 10 % (w/v) 
milk.  Further, three 10 minute washes were carried out. However, when probing for 
pPRH the pPRH antibody required three 30 minute washes.  
The proteins on the membrane were detected using the ECL western blotting 
detection solutions 1 and 2 (GE Healthcare RPN2106). Both solutions were mixed 
using a 1:1 ratio and used to soak the membranes, placed on Sarogold wrap for 
three minutes. Excess ECL reagent was removed and the membrane was wrapped 
in Sarogold wrap and exposed to ECL hyperfilm (GE Healthcare 28-9068-37) prior 
to detection using the developer, Xo-graph. 
 
2.3.7 M6 polyclonal antibody  
Due to limited availability of antibodies that are able to detect PRH protein 
expression in breast cells. A novel mouse monoclonal antibody was generated in 
the Jayaraman laboratory, called M6. The antibody was raised against the human 
peptide consisting of SPFLQRPLHK amino acids x to x in human PRH sequence. 
M6 is able to detect the endogenous PRH as a triplet of proteins with a molecular 
weight of approximately of 37 kD in haematopoietic cells and MCF-7, MCF-10A and 
MDA-MB-231 breast cells.  
 
2.3.8 Rabbit Polyclonal antibody  
In order to detect phosphorylated PRH expression the rabbit polyclonal antibody 
was used to confirm the phosphorylation of PRH by CK2 (Soufi, et al, 2009). 
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2.4 Puromycin Selection  
MCF-10A cells were counted using the method, see 2.2.3 and seeded in a 6 well 
plate at a density of ~200,000 cells per well and incubated overnight at 37°C. 10 
mg/ml puromycin was diluted in DMEM to make final concentrations  
0.5 µg/ml, 1 µg/ml, 5 µg/ml, 10 µg/ml, 50 µg/ml and 100 µg/ml. Cells were treated 
with each concentration until cell death had been observed. Photographs at each 
concentration were taken, after addition of the puromycin. Cell death was observed 
between 10 µg/ml and 50 µg/ml so additional 20 µg/ml and 30 µg/ml concentrations 
were made to treat the cells. Puromycin resistance was observed at 20 µg/ml so 
cells at this concentration were induced and grown.   
 
2.5 Plasmid 
2.5.1 pLKO-puro-IPTG-3xLacO (PRH and control shRNA) 
The sequence for PRH shRNA knockdown is CTGTGATCAGAGGCAAGATTT but 
the control sequence targets no known mammalian gene. WPRE enhances 
transgene expression and the LacI repressor binds to three LacO sequences that 
are present in the U6 promoter (Roberts, 2014 and Sigma Aldrich, 2014). This 
plasmid was used for the generation of inducible MCF-7, MCF-10A and MDA-MB-
231 PRH knockdown cell lines see 1.8. 
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Figure 2.2: Schematic of the pLKO-puro-IPTG-3xLacO  
Plasmid (Sigma Alrdrich, 2014).  
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RESULTS 
 
3.1 Introduction  
 Previous experimental work from our laboratory has shown that the K562 
leukaemic cells treated with dasatinib are more sensitive than K562 PRH 
knockdown cells (Noy, et al, 2012).  As outlined in section 1.4, dasatinib inhibits 
BCR-ABL and Src signalling in K562 cells, resulting in reduced CK2 activity which 
leads to a reduction in levels of pPRH. A reduction in pPRH protein level results in 
an increase in the transcriptionally active hypo-phosphorylated PRH protein. This 
active form of PRH is able to inhibit tumour growth by regulating the proteins 
involved in the VEGF signalling pathway. Thus, dasatinib reduces cell survival of 
the K562 leukemic cells which is mediated in part by PRH (Noy, et al, 2012). On the 
basis of these findings we further investigated whether dasatinib sensitivity follows a 
similar mechanism in reducing breast tumour survival in the MCF-7, MDA-MB-231 
and MCF-10A cell lines.  
 
3.2 Cell number is proportional to absorbance, following MTT incubation 
To determine whether breast cell viability is decreased with dasatinib treatment, cell 
viability assays were carried out. A cell viability assay measures mitochondrial 
activity and cell viability through the assessment of mitochondrial succinate 
dehydrogenase activity. The enzyme reduces the MTT reagent to formazan 
(purple), which is then visualised by a colorimetric change and measured 
spectrophotometrically at 545nm (Gerlier and Thomasset, 1986).  
In order to establish that there is a linear relationship between cell number and 
absorbance at 545 nm, for each cell line. Standard curves were generated for 
known cell number against absorbance. Initially, MCF-7 cells were seeded in 
quadruplicate at densities of 1562, 3125, 6250, 12,500, 25000 50,000 and 100,000 
cell/well in a 96 well plate.  The plate was incubated overnight at 37°C then 
incubated with the MTT reagent as described in 2.2.3. Figures 3.1 A and 3.1 C 
show that when cell number was plotted against absorbance, the absorbance was 
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not proportional to cell number above 50,000 cells for MCF-7 control and 
knockdown cells. Therefore, standard curves were re-plotted encompassing only 
the linear range where cell number was proportional to absorbance, shown in figure 
3.1 B and 3.1 D. Cell densities for the cell viability assays were selected so that 
subsequent to the 72 hour dasatinib treatment, cell number was within the linear 
range for the MCF-7 control and MCF-7 PRH knockdown cells.  
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Figure 3.1: Standard Curves for MCF-7 control (C5) and knockdown (KD5) 
cells. Absorbance readings at 545 nm were plotted against cell number for each 
cell line in order to determine the linear range where cell number is proportional to 
absorbance reading. Each standard curve was then re-potted and is displayed 
below its original standard curve where the linear range reflects cell number to be 
proportional to absorbance.  
(A) 
(B) 
(D) 
(C) 
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3.3 MCF-7 PRH control cells are more sensitive to dasatinib than MCF-7 
PRH knockdown cells   
To determine the concentration of dasatinib which results in decreased cell number 
in the MCF-7 control and knockdown cells, cell viability assays were performed in 
the presence of increasing concentrations of dasatinib: 0.05 µm, 0.1 µm, 0.5 µm 
and 1 µm. Cells were seeded at 5000 cells/well in a 96 well plate and allowed to 
adhere for 24 hours. They were then incubated with the equivalent volume of 
DMSO or with dasatinib for 72 hours. Cell viability assays were performed in 
quadruplicate for each dasatinib concentration. DMSO was used as the solvent to 
dissolve dasatinib and therefore an equal volume of DMSO was used as a control in 
all cell viability assays. It is well documented that DMSO has a cytotoxic effect upon 
the viability of some cell lines (Violante, et al, 2002). Therefore absorbance values 
were expressed as a percentage of the DMSO treated cells to control for any effects 
of DMSO on cell viability in these assays. Absorbance values for dasatinib treated 
samples were expressed as a percentage of the DMSO control, after the DMSO 
control was compared to the untreated cells. All experiments were carried out three 
independent times.  
A one-way ANOVA statistical test was used to show that statistically there is a 
significant reduction in cell viability following dasatinib treatment in both MCF-7 
control and MCF-7 PRH knockdown cells. An un-paired students’ t-test was then 
able to identify the concentration at which cell viability-was statistically significantly 
reduced for each cell line. Figure 3.2 shows that the viability of MCF-7 control cells 
is significantly reduced following treatment with 0.1 µm dasatinib whereas MCF-7 
PRH knockdown cells are more resistant showing significantly reduced viability 
following treatment with 1 µm dasatinib. Therefore a higher concentration of 
dasatinib is required to reduce the viability MCF-7 PRH knockdown cells.  
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Figure 3.2: Cell viability graphs for MCF-7 control and MCF-7 knockdown cells 
treated with dasatinib. MCF-7 control cells show a significant decrease in cell 
viability following treatment with 0.1 µm (p<0.01) dasatinib, whereas the MCF-7 
knockdown cells show a significant decrease in viability following treatment with 
dasatinib at higher concentration of 1 µm (p<0.01).  
*= p<0.05 **=p<0.01 
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3.4 Microarray Analysis 
Cell viability assays show that there is a difference between the MCF-7 control and 
MCF-7 PRH knockdown cells with dasatinib treatment. So, in order to determine the 
molecular basis of the dasatinib response in MCF-7 control and MCF-7 PRH 
knockdown cells, data from the MCF-7 microarray was used to identify known 
dasatinib target genes that have significantly altered gene expression in the MCF-7 
PRH knockdown cells. This is shown below in table 3.1. The MCF-7 microarray was 
generated and analysed by Dr Rachael Kershaw (Kershaw et al, submitted). We 
found that expression levels of the SFKs such as Fyn, Lyn and Yes are significantly 
up-regulated in the MCF-7 PRH knockdown cells. Interestingly, increased 
expression of EGFR and FGFR1 were also found but no increase in expression 
levels of c-KIT and PDGFR were observed.  
 
 
Table 3.1: Summary of gene expression of various dasatinib targets MCF-7 
control and PRH knockdown cells. Targets of dasatinib which are significantly up-
regulated when PRH is silenced in MCF-7 cells, shown by fold change. The 
microarray data was generated and validated by Dr Rachael Kershaw. 
    
Gene Fold Change KD/C 
Src Family Kinases (SKF): Fyn, Lyn, Yes 3.66 
Fibroblast Growth Factor Receptor 1 (FGFR1) 2.37 
Epidermal Growth Factor Receptor (EGFR) 7.49 
EPH receptor A2 (EPHA2) 4.78 
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3.5 MCF-7 cells sensitivity to dasatinib is partly mediated through PRH 
An analysis of the microarray data showed that several dasatinib targets are up-
regulated in MCF-7 PRH knockdown cells, suggesting that signalling through these 
targets underlies the difference in the effect of dasatinib on MCF-7 cell viability. We 
focused primarily on two questions, firstly, whether dasatinib inhibits EGFR and Src 
kinase signalling and downstream effector proteins such as pAKT, in the MCF-7 
control and knockdown cells. Secondly, whether there is a difference in signalling 
through EGFR and Src kinases between MCF-7 control and MCF-7 PRH 
knockdown cells.  
MCF-7 control and MCF-7 PRH knockdown cells were incubated with DMSO or 10 
µm dasatinib for 4 hours. Whole cell extracts were produced and 20 µg of protein 
was loaded on an SDS-PAGE gel for protein separation. Western blotting 
experiments were carried out where phosphoEGFR (pEGFR), phosphoSrc (pSrc), 
and phosphoAKT (pAKT) and Lamin A/C were probed for using their corresponding 
antibody. Lamin expression serves as a loading control and was used for all 
experimental work in this project. The western blots for the dasatinib treated MCF-7 
control and PRH knockdown cells were representative of three independent 
biological treatments whereas the pAKT blot was representative of two independent 
biological treatments.  
Figure 3.3A shows that levels of pSrc and pEGFR are elevated in the MCF-7 PRH 
knockdown cells compared to the MCF-7 control cells. This strongly suggests that 
increased Src and EGFR signalling occurs in cells expressing low amounts of the 
active PRH protein. However, levels of the unphosphorylated Src protein were not 
reproducibly elevated in the MCF-7 PRH knockdown cells. Indeed, the microarray 
data does not indicate an increase in the Src transcript in these cells, but does show 
elevated levels of other SFKs in the microarray see table 3.1. Interestingly, with 
dasatinib treatment levels of pEGFR expression was reduced in the MCF-7 PRH 
knockdown cells but pEGFR was not detected in the MCF-7 control cells, so no 
alteration in pEGFR expression could not be deduced in MCF-7 control cells. We 
believe this is because EGFR is not expressed at high levels in MCF-7 control cells.  
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AKT is an indirect downstream effector of Src and EGFR and is activated via the 
activation of PI3K and PDK1. The MCF-7 PRH knockdown microarray showed AKT 
to be highly up-regulated in MCF-7 PRH knockdown cells. Therefore, we decided to 
investigate levels of the active form of AKT, phosphorylated AKT (pAKT) by 
immunoblotting with an antibody against pAKT. Figure 3.3A shows that pAKT levels 
are not increased in the PRH knockdown cells compared to the MCF-7 control cells, 
suggesting that Src/EGFR signalling is not strongly influencing pAKT levels. 
Interestingly, dasatinib treatment resulting in reduced pAKT expression in the MCF-
7 control cells than in the MCF-7 PRH knockdown cells. This suggests that 
dasatinib can have some downstream effect on the active form of AKT. However as 
this is not seen in the MCF-7 PRH knockdown cells this is not the mechanism of 
dasatinib action in MCf-7 PRH knockdown cells that accounts for their resistance to 
dasatinib treatment.  
Surprisingly, we found elevated expression of pPRH in the MCF-7 PRH knockdown 
cells compared to the MCF-7 control cells. This is unexpected as the cells are 
known to have decreased expression of hypo-phosphorylated PRH detected by the 
M6 antibody. Interestingly, with dasatinib treatment pPRH levels are decreased in 
the MCF-7 PRH knockdown cells but there was no alteration of pPRH expression in 
MCF-7 control cells. We infer that the reduction in pPRH in the MCF-7 PRH 
knockdown cells upon treatment occurs because CK2 dependent phosphorylation 
of PRH is decreased. .  
As neither PI3/PDK1 nor CK2 are directly bound by dasatinib, we infer that pPRH is 
a downstream consequence of the inhibition of Src/EGFR signalling. Src and EGFR 
have been shown to interact directly with CK2 and influence its activity in many cell 
lines (Bliesath, et al, 2012). Findings from 3.3A led to the formation of the model 
shown in figure 3.3B. Here, dasatinib resistance of MCF-7 PRH knockdown cells 
occurs due to the reduction in level of PRH protein, which results in increased 
expression of multiple genes that are involved in tumour survival, including EGFR. 
Consequent effects on downstream signalling proteins such as Src and CK2, results 
in the elevated expression of transcriptionally inactive PRH protein and decreased 
growth inhibitory hypo-phosphorylated PRH protein. This leads to increased tumour 
survival. Therefore, higher activity and expression of dasatinib target proteins like 
EGFR and higher activity of pSrc, lead to the requirement of increased dasatinib 
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concentration for the inhibition of breast tumour cell survival. Ultimately, dasatinib 
resistance of MCF-7 PRH knockdown is a consequence of decreased PRH activity 
in these cells, resulting in increased tumour survival signalling.  
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(B) 
 
                                 
 
 
 
 
 
 
 
Tumour Survival 
Figure 3.3: (A) Western blotting to determine the protein levels of pEGFR, Src, 
pSrc, PRH and pPRH. (B) Model depicting the inhibition of EGFR and Src 
kinase activity which would lead to reduced CK2 activity and a reduction in the 
amount of phosphorylated PRH, reducing breast tumour cell survival. Src is a 
major regulator for the PI3K signalling pathway which is needed for the 
activation of AKT. As dasatinib is a Src inhibitor,by inhibiting Src kinase  activity 
this would also lead to a reduction in tumour cell survival via the PI3K pathway.  
(A) 
(B) 
EGFR 
Src 
CK2 
PRH 
DASATINIB 
DASATINIB 
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3.6 Cell Number proportional to absorbance, following MTT incubation for 
MDA-MB-231 control and knockdown cells.  
As dasatinib sensitivity is PRH dependent in the tumorigenic MCF-7 control cells, 
we decided to further investigate whether dasatinib sensitivity would be mediated 
through PRH in the highly metastatic MDA-MB-231 control and MDA-MB-231 PRH 
knockdown cells. Again to establish the relationship of cell number against 
absorbance in the MDA-MB-231 control and MDA-MB-231 PRH knockdown cells 
cell viability assays were carried out. Following the same procedure for the MCF-7 
standard curves, standard curves were plotted for the MDA-MB-231 control and 
MDA-MB-231 PRH knockdown cells. Figure 3.4 shows standard curves for the 
MDA-MB-231 cells where the absorbance was not proportional to cell number 
above 20,000 cells. Therefore standard curves were re-plotted encompassing only 
the linear range where cell number was proportional to absorbance, shown in figure 
3.4 B and 3.4 D. Cell densities for the cell viability assays were selected so that 
subsequent to the 72 hour dasatinib treatment, cell number was within the linear 
range for the MDA-MB-231 control and MDA-MB-231 PRH knockdown cells.  
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Figure 3.4: Cell Viability graphs for dasatinib treated MDA-MB-231 control (C2) 
and PRH knockdown (KD9) cells. MDA-MB-231 control cells were less sensitive to 
dasatinib compared to the MDA-MB-231 PRH knockdown cells. However, both cell 
lines are sensitive to dasatinib at the same dasatinib concentration 0.05 µm, but the 
PRH knockdown cells are more statistically significant at this concentration, 
suggesting that they are more sensitive to the treatment.  
 
(D) 
(C) 
(A) 
(B) 
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3.7 Dasatinib sensitivity in the MDA-MB-231 cells is not PRH dependent.  
PRH knockdown in MDA-MB-231 cells results in a decrease in cell proliferation 
whereas PRH MCF-7 cells result in increased proliferation (Roberts, 2014). Thus, 
the role of PRH in the MDA-MB-231 cells appears to be very different to that in the 
MCF-7 cells. Cell viability assays were carried out for the MDA-MB-231 control and 
knockdown cells, as described in section 2.2.3. These experiments were performed 
on three independent occasions. Figure 3.5 shows no difference in the response of 
dasatinib between the MDA-MB-231 control and MDA-MB-231 PRH knockdown 
cells. In support of this finding an analysis of MDA-MB-231 control and PRH 
knockdown microarray, did not reveal any significant change in gene expression 
levels of known dasatinib targets following PRH knockdown. 
A one-way ANOVA statistical test was used to show that statistically there is no 
significant reduction in cell viability following dasatinib treatment in both MCF-10A 
control and MCF-10A PRH knockdown cells. Thus, dasatinib sensitivity in the MDA-
MB-231 cells is not PRH dependent.  
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Figure 3.5: Cell Viability graphs for dasatinib treated MDA-MB-231 
control and PRH knockdown cells. MDA-MB-231 control and 
knockdown cells showed no significant difference between the cell 
lines. This strongly suggests that their sensitivity to dasatinib is not 
mediated via PRH.  
*= p<0.05 **=p<0.01 ***=p<0.001 
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3.8 Generation of MCF-10A control and knockdown cell lines with a 
stronger PRH knockdown 
The current MCF-10A PRH knockdown cells have a low amount of PRH protein 
compared to the MCF-7 PRH knockdown cells (PSJ, communications).  Therefore 
we attempted to generate a stronger MCF-10A PRH knockdown cell line. To do this 
we selected cells which could tolerate a greater puromycin concentration of 10 
µg/ml, compared to the original puromycin concentration 0.5 µg/ml. 
Puromycin is an aminonucleoside antibiotic which inhibits protein synthesis by 
causing premature chain termination, when the peptide transfer on the ribosomes is 
disrupted, during translation (Life Technologies, 2014). By increasing the puromycin 
resistance in both MCF-10A control and knockdown cell lines the aim was to 
produce a stronger knockdown cell line by selecting for cells where the lentivirus 
has randomly integrates into a region of open chromatin, thereby allowing a high 
level of expression of puromycin as well as other genes present in the same viral 
integration sites. 
MCF-10A control and knockdown cells were seeded at 200,000 cell/well in a 6 well 
plate and were left to adhere for 24 hours. Puromycin titrations were carried out in 
order to find the highest concentration of puromycin at which both MCF-10A control 
and MCF-10A PRH knockdown cells would survive. Initially MCF-10A control and 
MCF-10A knockdown cells were infected with 0.5 µg/ml, 10 µg/ml and 50 µg/ml  
puromycin. Figure 3.6 shows the alteration of cell morphology at 50 µg/ml when cell 
death had occurred in both MCF-10A control and MCF-10A PRH knockdown cells. 
Hence, 50 µg/ml puromycin was deemed too high and an additional puromycin 
titration was set up with the following concentrations of puromycin: 10 µg/ml, 20 
µg/ml and 30 µg/ml. After 5 days of incubation with the above puromycin 
concentrations, more cell death was observed following incubation with 30 µg/ml 
puromycin than with 20 µg/ml, shown in figure 3.6. 10 µg/ml was selected as the 
optimum puromycin concentration that the MCF-10A control and MCF-10A 
knockdown cells are able to tolerate. Western blotting was carried out to assess 
whether there was an increase in the MCF-10A PRH knockdown upon induction. 
However, PRH proteins in the MCF-10A control or MCF-10A PRH knockdown cells  
were not apparent in the western blotting experiments, therefore  additional western 
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blotting  experiments are necessary  to determine whether we successfully 
generated  a MCF-10A PRH knockdown cell with a more effective knockdown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Images of MCF-10A 10 µg/ml puromycin selection. Initially, puromycin 
titrations were carried out but for control and knockdown cells at 0.5 µg/ml, 10 µg/ml and 
50 µg/ml. Cell death was observed at 50 µg/ml and so this concentration was not used. 
Additional puromycin titrations were then set up using 10 µg/ml, 20 µg/ml and 30 µg/ml, 
cell death was observed at 30 µg/ml and so was not used and 10 µg/ml was selected as 
the optimum puromycin selection for the generation of a stronger PRH knockdown cell 
line. The cell line was grown and induced used for all experimental work.  
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3.9 MCF-10A control cells are more sensitive to dasatinib than MCF-10A 
PRH knockdown cells 
Although the MCF-10A cells were not found to be further knocked down for PRH, 
the parental MCF-10A PRH knockdown cells are known to be altered in comparison 
to the MCF-10A control cells. The difference being that MCF-10A PRH knockdown 
cells are more migratory (Kershaw, et al, 2013). Furthermore wound healing assays 
and transwell assays have shown the MCF-10A PRH knockdown cells to be more 
migratory than the MCF-10A control cells (Kershaw, et al, 2013). Thus, the high 
puromycin selected cells were used for cell viability assays to determine if a 
reduction in the level of PRH influences dasatinib sensitivity in this non-transformed 
cell line.  
A one-way ANOVA statistical test was used to show that statistically there is a 
significant reduction in cell viability following dasatinib treatment in both MCF-10A 
control and MCF-10A PRH knockdown cells. An un-paired students’ t-test was then 
able to identify the concentration at which cell viability-was statistically significantly 
reduced for each cell line. Figure 3.7 shows that the viability of MCF-10A control 
cells is significantly reduced following treatment with 0.1 µm dasatinib whereas 
MCF-10A PRH knockdown cells are more resistant, showing significantly reduced 
viability following treatment with 1 µm dasatinib. Therefore a higher concentration of 
dasatinib is required to reduce viability in MCF-10A PRH knockdown cells. Thus, 
the MCF-10A PRH knockdown cells are resistant to dasatinib sensitivity similar to 
the MCF-7 PRH knockdown cells.  
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Figure 3.7: Cell Viability graphs for dasatinib treated puromycin selected MCF-
10A control and knockdown cells. MCF10A control cells show a significant 
decrease in viability following treatment with 0.1 µm (p<0.01) dasatinib, whereas the 
MCF-10A knockdown cells show a significant decrease in viability following treatment 
with dasatinib at higher concentration of 1 µm (p<0.01).  
*= p<0.05 **=p<0.01 ***=p<0.001 
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DISCUSSION 
 
4.1 Introduction 
The single-agent dasatinib is an inhibitor of multiple oncogenic tyrosine kinases 
such as Src, c-kit and EGFR and has shown modest activity as monotherapy 
against breast tumour cells (Mayer and Krop, 2010, Mayer, et al, 2011 and Herold, 
et al, 2011). Here, we investigated whether dasatinib-induced inhibition is partly 
through PRH in various breast tumour cells lines MCF-7, MDA-MB-231 and MCF-
10A.   
4.2 Molecular mechanism of dasatinib action differs in K562 leukemic cells 
to MCF-7 breast tumour cells  
Previous experimental work from the Jayaraman laboratory has established that 
dasatinib treatment inhibits K562 leukemic cell survival, but a higher concentration 
of dasatinib is required to inhibit survival in the absence of PRH (Noy, et al, 2012).  
Figure 4.1 shows that the dual Src/ABL inhibitor reduces activity of the inactive form 
of PRH (pPRH) and elevates levels of hypo-phosphorylated PRH to re-establish the 
repression of the VSP genes. Thus, the effect of dasatinib is mediated via PRH to 
inhibit leukemic cell survival (Noy, et al, 2012).  
Although western blotting experiments show that K562 control cells have high 
pPRH levels in comparison to the K562 PRH knockdown cells. This was a contrast 
to the findings from the present study in MCF-7 cells. Here, we show that dasatinib 
decreases pPRH levels in the MCF-PRH knockdown cells but that there is no visible 
alteration in pPRH with dasatinib treatment in the MCF-7 control cells. This 
suggests that the basis for MCF-7 PRH knockdown resistance to dasatinib may 
differ from that observed in the K562 leukemic cells.  
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4.3 MCF-7 dasatinib sensitivity  
We showed that MCF-7 control cells have a significant decrease in cell viability 
following treatment with 0.1 µm (p<0.01) dasatinib, in comparison to the MCF-7 
PRH knockdown cells which are significantly more resistant to dasatinib at 1 µm 
(p<0.01). MCF-7 PRH knockdown cells are also more migratory and proliferative in 
comparison to MCF-7 control cells (Roberts, 2014).  
EGFR is a critical regulator and signal transducer in the inhibition of breast tumour 
growth (Kuraya, et al, 2004 and reviewed by Masuda, et al, 2012). EGFR is able to 
undergo auto-phosphorylation where ligand binding to the extracellular domain 
prompts dimerisation. This is caused by a conformational change in the EGFR 
monomers, stimulating EGFR kinase activity, leading to trans-auto-phosphorylation. 
This results in the phosphorylated tyrosine residue to act as a docking site for 
downstream protein signalling (Schulze, et al, 2005). We have shown that dasatinib 
decreases pEGFR levels in MCF-7 control cells and infer that dasatinib inhibits the 
phosphorylation of EGFR. This is also the site for trans-phosphorylation of Src 
(Nautiyal, et al, 2009). Auto-phosphorylation of Src is a type of post-translational 
modification whereby the kinase phosphorylates itself to sustain its active site. Src 
auto-phosphorylation results in greater levels of active Src and increased 
Figure 4.1: Model depicting the effect of dasatinib on PRH activity in 
chronic myeloid leukaemia (CML). Dasatinib affects the interaction 
between CK2 and BCR-ABL causing CK2 activity to be reduced, resulting in 
reduced p-PRH. Consequently, this re-establishes the repression of the VSP 
genes that lead to inhibition of leukaemic cell survival (Noy et al., 2012).  
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expression and/or of active downstream dasatinib targets/proteins. We have shown 
that dasatinib reduces the level of pSrc in MCF-7 control and MCF-7 PRH 
knockdown cells and infer that dasatinib reduces the amount of Src auto-
phosphorylation in order to decrease the amount of active Src. Thus, by reducing 
the activation of downstream signalling pathways which are regulated by Src, cell 
survival can be inhibited through the down-regulation of various downstream 
pathways such as the PI3K pathway.  
The PI3K pathway is transduced by AKT which effects cellular proliferation, 
programmed cell death and cell migration by the phosphorylation of substrates 
(Vogt, et al, 1999 and reviewed by Shtilbans, et al, 2007). Ligand-dependent 
binding of AKT to EGFR activates the receptor via auto-phosphorylation. 
Phosphatidyl inositol-3 kinase (PI3K) is activated by EGFR and converts 
phosphatidyl inositol-4,5 bisphosphate (PIP2) at the 3’ position of the inositol ring to 
PIP3. PIP3 is important for the activation of AKT via AKT phosphorylation. AKT 
phosphorylation is mediated through phosphatidyl inositol-3-phosphate dependent 
kinase (PDK1), which phosphorylates AKT, leading to the activation of AKT (Vogt, 
et al, 1999 and reviewed by Shtilbans, et al, 2007).  Here we have shown that levels 
of pAKT are only reduced in the MCF-7 control cells with dasatinib treatment and 
infer that dasatinib is not causing inhibition of pAKT in MCF-7 PRH knockdown cells 
and that this is not the reason for dasatinib resistance of the MCF-7 PRH 
knockdown cells.  
4.4 MDA-MB-231 dasatinib sensitivity  
MDA-MB-231 cells are known to be the most invasive, proliferative and 
mesenchymal breast cancer cell line. High expression of such genes that control 
migration and proliferation result in the up-regulation of various pathways that are 
associated with increased cell survival. Thus, a higher concentration of dasatinib 
would be expected to be required to down-regulate pathways to reduce tumour cell 
survival. No significant difference in response was found between the dasatinib 
treated MDA-MB-231 control and PRH knockdown cells in our cell viability assays. 
Findings from the MDA-MB-231 cell viability assays are in agreement with the 
microarray data, as no significant alteration in expression levels of known dasatinib 
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targets were found in the MDA-MB-231 PRH knockdown cells. Thus, in MDA-MB-
231 control cells dasatinib sensitivity is PRH dependent.  
 
4.5 MCF-10A dasatinib sensitivity  
The immortalised MCF-10 control cells exhibit a greater reduction in cell viability in 
comparison to MCF-10A PRH knockdown cells, which are relatively dasatinib 
resistant. We speculate that the mechanism by which the MCF-10A exhibits its 
dasatinib sensitivity is similar to the tumorigenic MCF-7 control and MCF-7 PRH 
knockdown cells. Further experiments are needed to test this hypothesis.  
4.6 MDA-MB-231 control cells more sensitive to dasatinib than MCF-7  
We have shown by cell viability assays that MCF-7 control cells have a greater 
reduction in cell viability compared to the MCF-7 and MDA-MB-231 PRH 
knockdown cells. This strongly suggests that the mechanism by which dasatinib is 
functioning is partly through PRH in the MCF-7 control cells. Interestingly, MDA-MB-
231 control cells are more sensitive to dasatinib at a lower concentration of 
dasatinib 0.05 µm (p<0.01) see figure 3.5. Whereas the MCF-7 control cells are 
significantly sensitive to dasatinib at a higher dasatinib concentration 0.1 µm 
(p<0.01), see figure 3.2. This finding is supported by other investigations that have 
found the MDA-MB-231 cell line to be more sensitive to dasatinib in comparison to 
other cell lines (Finn et al, 2006, Huang et al, 2007 and Park, et al, 2012).  
One study reported that the mesenchymal MDA-MB-231 cells have an altered 
cytoskeletal nature with dasatinib treatment (Pichot, et al, 200). Prior to treatment 
the MDA-MB-231 cells are spindle-shaped and grow as flattened cells, but with 
dasatinib treatment they are denser with compact cell bodies, with disrupted actin 
and tubulin structures. MDA-MB-231 dasatinib treated cells were observed to be 
round with less actin branching, reducing their mesenchymal nature (Pichot, et al, 
2009). Thus, dasatinib treatment is able to inhibit MDA-MB-231 cell growth (Pichot, 
et al, 2009). As such dramatic changes were not observed with the MCF-7 cells in 
this study; these findings offer some explanation as to why our findings have shown 
that  the highly PRH expressing MDA-MB-231 cells are more sensitive at a lower 
dose of dasatinib compared to the low PRH expressing MCF-7 cells. Significantly, 
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MDA-MB-231 cells that are known to express high amounts of the PRH protein 
(Roberts, 2014) are more sensitive to dasatinib treatment than MCF-7 cells that 
express low amounts of the PRH protein (Roberts, 2014). This difference supports 
the hypothesis that breast cells with low PRH are more resistant to dasatinib 
treatment. However, further investigations are needed to confirm this notion.  
 
4.7 Transcriptional Factors as biomarkers in Breast Cancer Therapy 
Many transcription factors are currently used in breast cancer management, 
however we have shown that dasatinib sensitivity is PRH dependent in MCF-7 and 
MCF-10A cells.   
Estrogen receptor (ER) expression is currently used to determine the sensitivity of 
patients to endocrine therapy, where high levels of ER are correlated with a better 
therapeutic response to endocrine therapy (reviewed by Marion, et al, 2010). HER2 
amplification is also currently used a biomarker where higher levels of the HER2 
oncogene are correlated with the increased chance of relapse and reduced survival 
(Pergram, et al, 2000 and reviewed by Marion, et al, 2010). Emerging biomarkers 
such as FOXA1, GATA3 and circulating microRNAs have also shown great 
potential in the improvement of breast cancer management. FOXA1 is a 
transcription factor essential for the development of mammary gland (Carroll and 
Brown, 2006 and reviewed by Qing, et al, 2014). One study has shown the potential 
of FOXA1 as a prognostic biomarker that is correlated with favourable clinical 
outcome in breast cancer (Mehta, et al, 2012 and reviewed by Qing, et al, 2014). 
GATA3 overexpression inhibits metastasis of breast cells, revealing its potential as 
a biomarker for breast cancer metastasis (Yan, et al, 2010). Furthermore, circulating 
microRNAs are emerging novel breast cancer biomarkers prior to the perioperative 
period. One study showed that cancer-specific miRNAs are altered in circulating 
breast tumour patients, where specifically miR-195 levels were increased 
(Heneghan, et al, 2010). Following curative resection miR-195 levels were 
significantly reduced in breast tumour patients, strongly indicating the use of 
miRNAs as non-invasive breast cancer biomarkers (Heneghan, et al, 2010). With 
the advancement in the production of biomarkers for breast cancer patients, this 
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study has shown the potential of the transcription factor PRH to be a biomarker to 
dasatinib treatment in breast cancer patients.   
 
4.8 Future Work  
In order to establish that dasatinib sensitivity is truly PRH dependent, additional cell 
viability assays should be carried out with additional control and PRH knockdown 
cell lines in the MCF-7, MCF-10A and MDA-MB-231 cell lines. Additional cell 
viability repeats are necessary for the MCF-10A control and MCF-10A PRH 
knockdown cells, as the reproducibility of the current cell viability assays is 
somewhat questionable. As our findings suggests that MCF-10A cells are PRH 
dependent in response to dasatinib treatment,  it would also be interesting to further 
understand the molecular mechanism by western blotting for signalling proteins 
involved in tumour cell survival in MCF-10A cells. Furthermore, blocking EGFR 
signalling with a specific EGFR inhibitor and then experimenting the effects of 
dasatinib treatment on control and PRH knockdown in these breast tumour cells cell 
lines. This would enhance our understanding into the mechanism by which the 
direct dasatinib target EGFR, can reduce breast tumour survival through various 
signalling pathways.  
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CONCLUSION 
The immortalised MCF-10A control cells are more sensitive to dasatinib treatment 
than the MCF-10A PRH knockdown cells.  Similarly, the tumorigenic MCF-7 control 
cells are more sensitive to dasatinib treatment than the MCF-7 PRH knockdown 
cells. Interestingly, the highly aggressive MDA-MB-231 control cells showed no 
significant difference to dasatinib treatment in comparison to the MDA-MB-231 PRH 
knockdown cells. Interestingly, the MDA-MB-231 control cells appear to be more 
sensitive to dasatinib treatment than the MCF-7 control cells. This is in agreement 
with current literature. The MCF-7 microarray data was used to identify the 
alteration in gene expression levels of known dasatinib target genes, in the MCF-7 
PRH knockdown cells. On identifying that EGFR and SFKs are highly up-regulated 
in the MCF-7 PRH knockdown cells, we used western blotting to gain an in depth 
understanding into the mechanism by which reduces breast tumour survival, 
through the active forms of EGFR (pEGFR) and Src (pSrc) with dasatinib treatment. 
We found that dasatinib inhibits EGFR and Src activity and infer that CK2 activity is 
inhibited as its substrate the inactive form of PRH (pPRH) is reduced with dasatinib 
treatment. Thus, our findings provide preliminary evidence that the transcription 
factor PRH has the potential in being a novel biomarker in breast cancer patients.  
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